LIST OF DRUG CANDIDATES TARGETING NASH
(updated weekly)

Click on the name of drug to access data sheet 


OCALIVA (OCA), Laboratory : INTERCEPT

Type of drug : FXR Agonist

Clinical trials advancement : Analysing Results Phase 3

The drug got the Breakthrough Therapy Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 9


ELAFIBRANOR (GFT505), Laboratory : GENFIT

Type of drug : dual PPAR alpha delta agonist

Clinical trials advancement : Ongoing Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 15


CENICRIVIROC (CENICRIVIROC), Laboratory : ALLERGAN

Type of drug : CCR2CCR5 Antagonist

Clinical trials advancement : Recruiting Phase 3

The drug got the Fast Track Status granted by the FDA and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 24


RESMETIROM (MGL_3196), Laboratory : MADRIGAL

Type of drug : THR-β Agonist

Clinical trials advancement : Recruiting Phase 3

and is eligible for Subpart H on intermediate results of Phase 3

Estimated Time to market in months : 30


BELAPECTIN (GR_MD_02), Laboratory : GALECTIN

Type of drug : Galectin Inhibitor

Clinical trials advancement : Initiating Phase 3

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 53


IMM124E (IMM124E), Laboratory : IMMURON

Type of drug : anti-LPS antibodies and adjuvants

Clinical trials advancement : Initiating Phase 3

The drug got the Breakthrough Therapy Status granted by the FDA

Estimated Time to market in months : 53


FIRSOCOSTAT (GS0976), Laboratory : GILEAD

Type of drug : ACC inhibitor

Clinical trials advancement : Initiating Phase 3

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 54


ARAMCHOL (ARAMCHOL), Laboratory : GALMED

Type of drug : FABACs

Clinical trials advancement : Analysing Results Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 53


CILOFEXOR (GS9674), Laboratory : GILEAD

Type of drug : FXR agonist

Clinical trials advancement : Analysing Results Phase 2b

Estimated Time to market in months : 78


MSDC_0602 (MSDC_0602), Laboratory : CIRIUS_THERAPEUTICS

Type of drug : mTOT modulating insulin sensitizer

Clinical trials advancement : Analysing Results Phase 2b

Estimated Time to market in months : 86


TROPIFEXOR (LJN452), Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 90


SEMAGLUTIDE (SEMAGLUTIDE), Laboratory : NOVONORDISK

Type of drug : GLP_1analog

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 90


LANIFIBRANOR (IVA337), Laboratory : INVENTIVA

Type of drug : tri PPAR α δ γ

Clinical trials advancement : Ongoing Phase 2b

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 67


SAROGLITAZAR (SAROGLITAZAR), Laboratory : ZYDUS

Type of drug : dual PPAR-α γ agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 90


SELADELPAR (MBX_8025), Laboratory : CYMABAY_THERAPEUTICS

Type of drug : PPAR delta receptor agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 98


NGM282 (NGM282), Laboratory : NGMBioPHARM

Type of drug : FGF19 hormon

Clinical trials advancement : Ongoing Phase 2b

Estimated Time to market in months : 92


LMB763 (LMB763), Laboratory : NOVARTIS

Type of drug : non-BA FXR agonist

Clinical trials advancement : Recruiting Phase 2b

Estimated Time to market in months : 94


PLX_065 (DRX_065), Laboratory : POXEL

Type of drug : stabilized, preferred enantiomer of pioglitazone

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 80


ISOSABUTATE (ISOSABUTATE), Laboratory : NORTHSEA_THERAPEUTICS

Type of drug : SEFA Structurally Engineered Fatty Acid

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 112


PF_06835919 (PF_06835919), Laboratory : PFIZER

Type of drug : Ketohexokinase (KHK) Inhibitor

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 112


BMS986036 (BMS986036), Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 104


EYP001 (EYP001), Laboratory : ENYOPHARMA

Type of drug : Non BA FXR agonist

Clinical trials advancement : Initiating Phase 2b

Estimated Time to market in months : 112


GRI_0621 (GRI_0621), Laboratory : GRIPharma

Type of drug : NKT I Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 112


BMS_986171 (pegbelfermin), Laboratory : Bristol-MyersSquibb

Type of drug : PEG-FGF21

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 112


VK2809 (VK2809), Laboratory : VIKING

Type of drug : THR-? Agonist prodrug

Clinical trials advancement : Analysing Results Phase 2a

Estimated Time to market in months : 94


PF_05221304 (PF_05221304), Laboratory : PFIZER

Type of drug : Acetyl CoA-Carboxylase (ACC) Inhibitor

Clinical trials advancement : Analysing Results Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 90


TIPELUKAST (TIPELUKAST), Laboratory : MEDICINOVA

Type of drug : (5-LOLT) inibitor

Clinical trials advancement : Analysing Results Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 90


NALMEFENE (JKB121), Laboratory : TaiwanJPharmaceuticals

Type of drug : Opioid receptor antagonists; Toll-like receptor 4 antagonists

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 114


PF_06865571 (PF_06865571), Laboratory : PFIZER

Type of drug : Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 114


LIK066 (LIK066), Laboratory : NOVARTIS

Type of drug : SGLT1-SGLT2 inhibitor

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 114


TESAMORELIN (EGRIFTA), Laboratory : Theratechnologies

Type of drug : growth hormone releasing hormone (GHRH) analogue

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 96


DF102 (AF102), Laboratory : AFIMMUNE

Type of drug : Undefined mechanism

Clinical trials advancement : Ongoing Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 91


NAMODENOSON (NAMODENOSON), Laboratory : CANFITE

Type of drug : A3AR Agonist

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 116


MT_3995 (MT-3995), Laboratory : MitsubishiTanabePharma

Type of drug : Aldosterone receptor antagonists

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 117


NITAZOXANIDE (NITAZOXANIDE), Laboratory : GENFIT

Type of drug : Stellate Cell activation

Clinical trials advancement : Ongoing Phase 2a

Estimated Time to market in months : 95


BI_1467335 (BI_1467335 or PXS-4728A), Laboratory : Boehringer_Ingelheim

Type of drug : VAP-1/AOC3 protein inhibitor

Clinical trials advancement : Ongoing Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 94


HTD1801 (HTD1801), Laboratory : HighTideTherapeutics

Type of drug : unknown mechanism of action

Clinical trials advancement : Recruiting Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 96


GEMCABENE (GEMCABENE), Laboratory : GEMPHIRE

Type of drug : enhance the clearance of VLDLs and may also inhibit ACC

Clinical trials advancement : Recruiting Phase 2a

Estimated Time to market in months : 121


FORALUMAB (FORALUMAB), Laboratory : TIZIANA

Type of drug : anti-CD3 monoclonal antibody (mAbs)

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 122


PXL770 (PXL770), Laboratory : POXEL

Type of drug : (AMPK) activator

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


BIO89_100 (BIO89_100), Laboratory : 89BIO

Type of drug : glycopegylated FGF21 analogue

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 115


SGM_1019 (SGM_1019), Laboratory : SecondGenome

Type of drug : P2X7 inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 122


CER_209 (CER_209), Laboratory : CERENIS

Type of drug : P2Y13 receptor agonist

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


HEPASTEM (HEPASTEM), Laboratory : PROMETHERA

Type of drug : human liver derived mesenchymal stem

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


BEZAFIBRATE (BEZAFIBRATE), Laboratory : INTERCEPT

Type of drug : tri PPAR alpha delta gamma

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 129


ELOBIXIBAT (A4250), Laboratory : AlbireoPharma

Type of drug : ileal bile acid transported (IBAT)

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


TERN_101 (TERN_101), Laboratory : TERNS

Type of drug : FXR Agonist

Clinical trials advancement : Initiating Phase 2a

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 99


SOTAGLIFLOZIN (LX4211), Laboratory : SANOFI

Type of drug : DUAL SGLT1 SGLT2 Inhibitor

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


SAR425899 (SAR425899), Laboratory : SANOFI

Type of drug : GLP-1/GCGR agonist

Clinical trials advancement : Initiating Phase 2a

Estimated Time to market in months : 123


KBP_042 (KBP_042), Laboratory : NORDICBIOSCIENCE

Type of drug : (DACRA)

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 123


DUR928 (DUR_928), Laboratory : DURECT

Type of drug : epigenetically-active endogenous small molecule

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 124


NGM313 (MK-3655), Laboratory : Merck/NGMBio

Type of drug : β-Klotho/FGFR1c receptor

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 124


LPCN_1144 (LPCN_1144), Laboratory : LIPOCINE

Type of drug : novel oral prodrug of testosterone containing testosterone undecanoate

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 127


NAMACIZUMAB (RYI-018 or JNJ-2463), Laboratory : BIRDROCKBIO

Type of drug : NAMA-CB1

Clinical trials advancement : Analysing Results Phase 1

Estimated Time to market in months : 127


RTU_1096 (RTU_1096), Laboratory : SUCAMPO

Type of drug : Vap-1 inhibitor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 128


ND_L02_s0201 (ND_L02_s0201), Laboratory : NITTODENKO

Type of drug : (SERPINH1) (Hsp47)

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 128


IONIS_DGAT2Rx (IONIS_DGAT2Rx), Laboratory : IONISPHARMA

Type of drug : DGAT2Rx

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 129


INT_767 (INT_767), Laboratory : INTERCEPT

Type of drug : farnesoid X receptor (FXR) and TGR5, a G-protein coupled bile acid receptor

Clinical trials advancement : Ongoing Phase 1

Estimated Time to market in months : 131


EDP_305 (EDP_305), Laboratory : ENANTA

Type of drug : FXR agonist

Clinical trials advancement : Recruiting Phase 1

The drug got the Fast Track Status granted by the FDA

Estimated Time to market in months : 107


CM_101 (CM_101), Laboratory : ChemomAb

Type of drug : anti CCL24 monoclonal antibody

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 134


TERN_201 (TERN_201), Laboratory : TERNS

Type of drug : SSAO Inhibitor

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 134


HM15211 (HM15211), Laboratory : HanmiPharmaceutical

Type of drug : long-acting GLP-1, GIP and glucagon triple agonist

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 134


NC_001 (NC_001), Laboratory : NAIAPHARMA

Type of drug : act on insulin resistance

Clinical trials advancement : Recruiting Phase 1

Estimated Time to market in months : 134


CRV431 (CRV431), Laboratory : HepionPharmaceuticals

Type of drug : cyclophilin inhibitor

Clinical trials advancement : Preclinic

Estimated Time to market in months : 122


VK0214 (VK0214), Laboratory : VIKING

Type of drug : TRβ agonist

Clinical trials advancement : Preclinic

Estimated Time to market in months : 134


BFKB8488A (BFKB8488A), Laboratory : Genentech-ROCHE

Type of drug : Anti-FGFR1 - KLB MAb

Clinical trials advancement : Preclinic

Estimated Time to market in months : 134


NV556 (NV556), Laboratory : NeuroVivePharmaceuticalAB

Type of drug : mild mitochondrial protonophores

Clinical trials advancement : Preclinic

Estimated Time to market in months : 134


AZD2693 (IONIS_AZ6_2.5_LRx), Laboratory : IONISPHARMA_ASTRAZENECA

Type of drug : NON DISCLOSED

Clinical trials advancement : Preclinic

Estimated Time to market in months : 134


NEULIV (INB03), Laboratory : INMUNEBIO

Type of drug : second- generation selective TNF inhibitor

Clinical trials advancement : Preclinic

Estimated Time to market in months : 134


NP160 (NP160), Laboratory : NashPharmaceuticals

Type of drug : ??

Clinical trials advancement : Preclinic

Estimated Time to market in months : 133


SP_1373 (VPD107), Laboratory : SPITFIRE_PHARMA

Type of drug : GLP1 Analog dual

Clinical trials advancement : Preclinic

Estimated Time to market in months : 135


RLBN1127 (RLBN1127), Laboratory : ACQUIST

Type of drug : Bifonctional Urates Inhibitors

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


NP135 (NP135), Laboratory : NashPharmaceuticals

Type of drug : ??

Clinical trials advancement : Preclinic

Estimated Time to market in months : 134


GKT_137831 (GKT_137831), Laboratory : GENKYOTEC

Type of drug : NOX1&4 inhibitor

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


VPR_423 (VPR_423), Laboratory : VisionaryPharmaceuticals

Type of drug : RORgammaT

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


RYI_018 (RYI_018), Laboratory : CREATIVEBIOLAB

Type of drug : (CB-1)

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


CB4209-CB4211 (CB4209-CB4211), Laboratory : CohBar

Type of drug : MOTS-c peptide analog

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


NVP022 (NVP022), Laboratory : NeuroVivePharmaceuticalAB

Type of drug : mild mitochondrial protonophores

Clinical trials advancement : Preclinic

Estimated Time to market in months : 136


The dynamic list is here 



Share on StockTwits
FR-flag

WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE